-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On August 5, Liaoning Sunshine Private Equity Fund Management .
, L.
(hereinafter referred to as Liaoning Sunshine Private Equity), a subsidiary of 3SBio, completed the fili.
This company is 100% funded and established by Liaoning Sunshine Pharmaceutical .
, L.
, and the actual controller is Sunshine Pharmaceutic.
It is understood that there are more than one private equity fund managers under 3SB.
In February 2017, Liaoning 3SBio was established and completed the filing in early 201This institution was established by Shenyang Sunshine Pharmaceutical .
, L.
and another company with 50% of their respective contributions, and manages a fund, namely the Liaoning Sunshine Medical Industry Investment Fund Partnership (Limited Partnership) established in 201In fact, it has become the norm for listed pharmaceutical companies to get together as limited partners (LP), and dozens of pharmaceutical companies have entered the market during the year, including 3SBio, Hengrui, Jichuan, Anxu Bio, Inke Medical, Steady Medical, e.
Hengrui Medicine announced on the evening of June 6 that the company intends to jointly initiate the establishment of a private equity investment fund partnership with its holding subsidiaries Shengdi Investment and Hengrui Gro.
The total subscribed capital contribution of the partnership is 010 billion yuan, of which Shengdi Investment, as a general partner (GP), contributed 10 million yuan, with a shareholding ratio of 5%; the company and Hengrui Group, as LPs, respectively contributed 1 billion yuan and held The shareholding ratios were 47
The company stated that the purpose of setting up the private equity this time is to enhance the company's capital operation ability and deepen the company's industrial layout, and the investment fund will carry out equity investment business around the medical and health indust.
Jichuan Pharmaceutical issued an announcement one day after Hengrui, saying that the company's participation in the subscription of fund shares has made new progre.
Previously, the company as an LP contributed 30 million yuan with its own funds to participate in the subscription of the Suzhou Industrial Park Xinjianyuan Phase IV Equity Investment Partnership (Limited Partnership), and has completed the registration procedures for private investment fun.
According to reports, the fourth phase of Xinjianyuan is mainly for investment in the medical and health fie.
Anxu Biology announced on June 3 that the company intends to use its own funds to fund the establishment of Hangzhou Zhongchuan Anxu Equity Investment with Zhongchuan Financial Holdings (Tianjin) Equity Investment Fund Management .
, L.
and Guohan Investment Management (Beijing) .
, L.
Partnership (limited partnership), the investment fund will be used for enterprises or projects in the fields of medicine, general health, and biomedicine in the start-up and growth stag.
The total amount of the fund to be invested and established this time shall not exceed 1 billion yuan, of which the company intends to subscribe and contribute no more than 500 million yuan with its own funds, and the proportion of investment shall account for 50% of the total investment of the fu.
The initial investment amount is 200 million yuan, accounting for 40% of the total subscribed capital contributi.
However, due to its participation in matters related to investment in industrial funds, the company received a regulatory work letter issued by the Shanghai Stock Exchange on JuneOn June 1, Intech Medical issued an announcement on participating in the investment in Innovatus Lower Middle Market Value Offshore Fund I, .
The announcement stated that, in order to further optimize the investment structure and enhance the investment value, the company's wholly-owned subsidiary Intech Medical Singapore intends to cooperate with " Innovatus” signed the Subscription Agreement to invest in the partnership with its own fun.
The total subscribed capital contribution of the partnership shall not exceed USD 400 million (the currency is USD, the same below), of which the company will subscribe to contribute USD 5 million as the limited partner (LP) of the partnersh.
Judging from the public information during the year, Inke Medical has a wide range of investment fields, involving medical health, consumer technology, new generation information technology and other fiel.
The company hopes to further optimize the investment structure and enhance the investment val.
It can be seen from the announcements of the above listed companies that most of the investment tracks for LP investment belong to the medical and health fie.
These companies choose to be LPs, which will help inject more vitality into the equity investment market, and can also expand through L.
own layo.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
, L.
(hereinafter referred to as Liaoning Sunshine Private Equity), a subsidiary of 3SBio, completed the fili.
This company is 100% funded and established by Liaoning Sunshine Pharmaceutical .
, L.
, and the actual controller is Sunshine Pharmaceutic.
It is understood that there are more than one private equity fund managers under 3SB.
In February 2017, Liaoning 3SBio was established and completed the filing in early 201This institution was established by Shenyang Sunshine Pharmaceutical .
, L.
and another company with 50% of their respective contributions, and manages a fund, namely the Liaoning Sunshine Medical Industry Investment Fund Partnership (Limited Partnership) established in 201In fact, it has become the norm for listed pharmaceutical companies to get together as limited partners (LP), and dozens of pharmaceutical companies have entered the market during the year, including 3SBio, Hengrui, Jichuan, Anxu Bio, Inke Medical, Steady Medical, e.
Hengrui Medicine announced on the evening of June 6 that the company intends to jointly initiate the establishment of a private equity investment fund partnership with its holding subsidiaries Shengdi Investment and Hengrui Gro.
The total subscribed capital contribution of the partnership is 010 billion yuan, of which Shengdi Investment, as a general partner (GP), contributed 10 million yuan, with a shareholding ratio of 5%; the company and Hengrui Group, as LPs, respectively contributed 1 billion yuan and held The shareholding ratios were 47
The company stated that the purpose of setting up the private equity this time is to enhance the company's capital operation ability and deepen the company's industrial layout, and the investment fund will carry out equity investment business around the medical and health indust.
Jichuan Pharmaceutical issued an announcement one day after Hengrui, saying that the company's participation in the subscription of fund shares has made new progre.
Previously, the company as an LP contributed 30 million yuan with its own funds to participate in the subscription of the Suzhou Industrial Park Xinjianyuan Phase IV Equity Investment Partnership (Limited Partnership), and has completed the registration procedures for private investment fun.
According to reports, the fourth phase of Xinjianyuan is mainly for investment in the medical and health fie.
Anxu Biology announced on June 3 that the company intends to use its own funds to fund the establishment of Hangzhou Zhongchuan Anxu Equity Investment with Zhongchuan Financial Holdings (Tianjin) Equity Investment Fund Management .
, L.
and Guohan Investment Management (Beijing) .
, L.
Partnership (limited partnership), the investment fund will be used for enterprises or projects in the fields of medicine, general health, and biomedicine in the start-up and growth stag.
The total amount of the fund to be invested and established this time shall not exceed 1 billion yuan, of which the company intends to subscribe and contribute no more than 500 million yuan with its own funds, and the proportion of investment shall account for 50% of the total investment of the fu.
The initial investment amount is 200 million yuan, accounting for 40% of the total subscribed capital contributi.
However, due to its participation in matters related to investment in industrial funds, the company received a regulatory work letter issued by the Shanghai Stock Exchange on JuneOn June 1, Intech Medical issued an announcement on participating in the investment in Innovatus Lower Middle Market Value Offshore Fund I, .
The announcement stated that, in order to further optimize the investment structure and enhance the investment value, the company's wholly-owned subsidiary Intech Medical Singapore intends to cooperate with " Innovatus” signed the Subscription Agreement to invest in the partnership with its own fun.
The total subscribed capital contribution of the partnership shall not exceed USD 400 million (the currency is USD, the same below), of which the company will subscribe to contribute USD 5 million as the limited partner (LP) of the partnersh.
Judging from the public information during the year, Inke Medical has a wide range of investment fields, involving medical health, consumer technology, new generation information technology and other fiel.
The company hopes to further optimize the investment structure and enhance the investment val.
It can be seen from the announcements of the above listed companies that most of the investment tracks for LP investment belong to the medical and health fie.
These companies choose to be LPs, which will help inject more vitality into the equity investment market, and can also expand through L.
own layo.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
